¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Myeloid-Lymphoid Leukemia Protein"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
¿µ¹® protein ÇÑ±Û ´Ü¹éÁú
¼³¸í   
  Åº¼Ò, ¼ö¼Ò, »ê¼Ò, Áú¼Ò, È²À» ÇÔÀ¯Çϰí Àִ À¯±âÈ­ÇÕ¹°·Î, ¸ðµç ¼¼Æ÷ÀÇ ¿øÇüÁúÀ» ÀÌ·ç°í Àִ ±âº» ±¸¼º¹°ÁúÀÌ´Ù. ´Ü¹éÁúÀº ±× ´ÜÀ§ÀΠ¾Æ¹Ì³ë»êµéÀÌ ÆéƼµå°áÇÕ¿¡ ÀÇÇØ °áÇյǾî ÀÖÀ¸¸ç, º¸Åë 20°³ÀÇ ¾Æ¹Ì³ë»êµéÀÌ ´Ù¸¥ ¼ø¼­¿Í Á¶¼ºÀ» °¡Áö°í ¹è¿­µÇ¾î, µ¶Æ¯ÇÑ ÇϳªÀÇ ´Ü¹éÁúÀ» Çü¼ºÇϰԠµÈ´Ù.
¿µ¹® chronic lymphocytic leukemia ÇÑ±Û ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´
¼³¸í   
  ¹éÇ÷º´(leukemia)¶õ ºñÁ¤»óÀûÀΠ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀΠ»óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊÇ÷¾×¿¡ ¹ÌºÐÈ­¼¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀΠÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀΠ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ Ã£¾Æ¿À°Ô µÈ´Ù. µû¶ó¼­ ÀûÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ¡°Ô ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³­´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇϴ °ñ¼ö Á¶Á÷¿¡¼­´Â ÀÌ·± ºñÁ¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù.
  
  ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´Àº ¼­¾ç¿¡¼­´Â ºñ±³Àû ¹éÇ÷º´ Áß¿¡¼­ ÈçÇÑ ÇüÀÌÁö¸¸ µ¿¾ç±Ç¿¡¼­´Â ¾ÆÁÖ µå¹® ¹éÇ÷º´ÀÇ ÇüÅÂÀÌ´Ù. ´ë°³ 60¼¼ ÀÌ»óÀÇ °í·ÉÃþ¿¡¼­ ¸¹ÀÌ »ý±â°í 30¼¼ ÀÌÇÏ¿¡¼­´Â °ÅÀǠã¾Æº¼ ¼ö°¡ ¾ø´Ù. Ç÷¾×°Ë»ç»ó¿¡¼­ ¸²ÇÁ±¸ÀÇ ¸¹Àº Áõ°¡¸¦ º¼ ¼ö°¡ ÀÖ°í, ´ë½Å¿¡ ´Ù¸¥ Ç÷¾×¼¼Æ÷µéÀº °¨¼Ò¸¦ ³ªÅ¸³½´Ù. ¹éÇ÷º´ Áß ¿¹Èİ¡ ÁÁÀº ÆíÀ̸破밳 Ä¡·á´Â Ç×¾ÏÁ¦¸¦ ÀÌ¿ëÇÑ È­Çпä¹ýÀ» ¸¹ÀÌ »ç¿ëÇϸç, Æò±Õ »ýÁ¸±â°£Àº 4~5³âÀÌ´Ù.
¿µ¹® leukemia ÇÑ±Û ¹éÇ÷º´
¼³¸í   
  ºñÁ¤»óÀûÀΠ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀΠ»óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊ Ç÷¾×¿¡ ¹ÌºÐÈ­¼¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀΠÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀΠ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ Ã£¾Æ¿À°Ô µÈ´Ù. µû¶ó¼­ ÀûÇ÷±¸ ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ£ ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³­´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇϴ °ñ¼ö Á¶Á÷¿¡¼­´Â ÀÌ·± ºñÁ¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù.
  
  ÀÌ·± ¹éÇ÷º´¿¡´Â ¿©·¯ °¡Áö°¡ Àִ µ¥ Å©°Ô 4°¡Áö·Î ³ª´©¾î ºÐ·ùÇÑ´Ù. Á¤»óÀûÀ¸·Î ¹éÇ÷±¸¼¼Æ÷´Â ¸²ÇÁ°è¼¼Æ÷¿Í °ñ¼ö°è¼¼Æ÷·Î 2ºÐµÇ´Âµ¥, ¹éÇ÷º´ ¶ÇÇÑ ÀÌ·± ¸²ÇÁ°è¼¼Æ÷ÀÇ Áõ½Ä°ú °ñ¼ö°è¼¼Æ÷ÀÇ Áõ½Ä¿¡ µû¶ó ³ª´©¸ç, ±× Áõ»óÀÌ ¾ó¸¶³ª »¡¸® ³ªÅ¸³ª´Â °¡¿¡ µû¶ó ¸¸¼º, ±Þ¼ºÀ¸·Î ³ª´«´Ù. µû¶ó¼­ ¿©±â¿¡´Â ´ÙÀ½ 4°¡ÁöÀÇ ºÐ·ù°¡ ³ª¿À°Ô µÈ´Ù.
  
  -±Þ¼º¸²ÇÁ¼º ¹éÇ÷º´: acute lymphocytic
  
  -±Þ¼º°ñ¼ö¼º ¹éÇ÷º´: acute myelogenous
  
  -¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´: chronic lymphocytic
  
  -¸¸¼º°ñ¼ö¼º ¹éÇ÷º´: chronic myelogenous.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • aplastic leukemia
    °ñ¼ö¹«Çü¼º¹éÇ÷º´
  • acute lymphocytic leukemia
    ±Þ¼º¸²ÇÁ±¸¹éÇ÷º´
  • acute myelocytic leukemia
    ±Þ¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute promyelocytic leukemia
    ±Þ¼ºÀü°ñ¼ö¼¼Æ÷¹éÇ÷º´, ±Þ¼ºÇ²°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute undifferentiated leukemia
    ±Þ¼º¹ÌºÐÈ­¹éÇ÷º´
  • adult T-cell leukemia/lymphoma
    ¼ºÀÎT¼¼Æ÷¹éÇ÷º´/¸²ÇÁÁ¾
  • aleukemic leukemia
    ¹«¹éÇ÷¼º¹éÇ÷º´
  • chloroma leukemia
    ³ì»öÁ¾¹éÇ÷º´
  • chronic lymphoblastic leukemia/small lymphocytic lymphoma
    ¸¸¼º¸²ÇÁ¸ð±¸¹éÇ÷º´/¼Ò¸²ÇÁ±¸¸²ÇÁÁ¾
  • chronic lymphocytic leukemia
    ¸¸¼º¸²ÇÁ±¸¹éÇ÷º´
  • chronic myelocytic leukemia
    ¸¸¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • eosinophilic leukemia
    È£»ê±¸¹éÇ÷º´
  • granulocytic leukemia
    °ú¸³±¸¹éÇ÷º´
  • hairy cell leukemia
    Åм¼Æ÷¹éÇ÷º´
  • leukemia
    ¹éÇ÷º´
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukemia cutis
    ÇǺιéÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • protein binding
    ´Ü¹é°áÇÕ
  • protein-losing enteropathy
    ´Ü¹é¼Ò½ÇâÀÚº´Áõ
  • protein
    ´Ü¹é, ´Ü¹éÁú
  • adherence protein
    ºÎÂø´Ü¹é
  • reserve protein
    ÀúÀå´Ü¹é
  • split-timed urine protein
    ½Ã°£´ëº°¿ä´Ü¹éÁ¤·®
  • structural protein
    ±¸Á¶´Ü¹é, ±¸Á¶´Ü¹éÁú
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acute undifferentiated leukemia
    ±Þ¼º¹ÌºÐÈ­¹éÇ÷º´
  • aleukemic leukemia
    ¹«¹éÇ÷¼º¹éÇ÷º´
  • aplastic leukemia
    °ñ¼ö¹«Çü¼º¹éÇ÷º´
  • chloroma leukemia
    ³ì»öÁ¾¹éÇ÷º´
  • granulocytic leukemia
    (¢¡myelogenous leukemia) °ñ¼ö¹éÇ÷º´
  • hairy cell leukemia
    Åм¼Æ÷¹éÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • leukopenic leukemia
    (¢¡aleukemic leukemia) ¹«¹éÇ÷¼º¹éÇ÷º´
  • lymphatic leukemia
    (¢¡lymphoblastic leukemia) ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphoblastic leukemia
    ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphocytic leukemia
    (¢¡lymphoblastic leukemia) ¸²ÇÁ¸ð±¸¹éÇ÷º´
  • lymphosarcoma cell leukemia
    ¸²ÇÁÀ°Á¾¼¼Æ÷¹éÇ÷º´
  • megakaryocytic leukemia
    °ÅÇÙ±¸¹éÇ÷º´, °Å´ëÇÙ¼¼Æ÷¹éÇ÷º´
  • monocytic leukemia
    ´ÜÇÙ±¸¹éÇ÷º´
  • monomyelogenous leukemia
    ´ÜÇÙ±¸°ñ¼ö¹éÇ÷º´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Burkitts acute lymphoblastic leukemia
    ¹öŰƮ ±Þ¼º ¸²ÇÁ¾Æ±¸¼º ¹éÇ÷º´
  • FAB =>French-american-British leukemia classification
    FAB ¹éÇ÷º´ºÐ·ù
  • French-American-British leukemia classification
    FAB ¹éÇ÷º´ºÐ·ù
  • Leukemia
    ¹éÇ÷º´(ÛÜúìÜ»)
  • T cell leukemia
    T¼¼Æ÷(¹éÇ÷º´
  • acute granulocytic leukemia
    ±Þ¼º °ú¸³±¸(¼º) ¹éÇ÷º´(¡­Î¨í£Ï¹àõÛÜúìÜ»).
  • acute granulocytic leukemia
    ±Þ¼º °ú¸³±¸(¼º) ¹éÇ÷º´(??ËöË´ËÛËÑÌ´ËÓ).
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´(¡­ÛÜúìÜ»).
  • acute monocytic leukemia
    ±Þ¼º ´Ü±¸(¼º) ¹éÇ÷º´(?ËÀË´ËÛËÑÌ´ËÓ).
  • acute myeloblastic leukemia
    ±Þ¼º °ñ¼ö¸ð¼¼Æ÷¼º ¹éÇ÷º´.
  • acute myeloblastic leukemia
    ±Þ¼º °ñ¼ö¸ð¼¼Æ÷¼º ¹éÇ÷º´.
  • acute myelocytic leukemia =AML
    ±Þ¼º °ñ¼ö±¸¼º ¹éÇ÷º´.
  • acute myelogenous leukemia
    ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(¡­ÍéâÐàõÛÜúìÜ»).
  • acute myelogenous leukemia
    ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´(?Ë­ËàËÛËÑÌ´ËÓ).
  • acute myelomonocytic leukemia
    ±Þ¼º °ñ¼ö´Ü±¸ ¹éÇ÷º´
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukemia cutis<³ª> leukemia of the skin
    ÇǺÎ(ù«Ý±)¹éÇ÷º´
  • acute granulocytic leukemia
    ±Þ¼º °ú¸³±¸(¼º) ¹éÇ÷º´(??ËöË´ËÛËÑÌ´ËÓ).
  • acute granulocytic leukemia
    ±Þ¼º °ú¸³±¸(¼º) ¹éÇ÷º´(¡­Î¨í£Ï¹àõÛÜúìÜ»).
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´(?ËÑÌ´ËÓ).
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´(¡­ÛÜúìÜ»).
  • acute leukemia virus
    ±Þ¼º¹éÇ÷º´¹ÙÀÌ·¯½º
  • acute lymphatic leukemia =ALL
    ±Þ¼º ¸²ÇÁ¼º ¹éÇ÷º´(?ËÛËÑÌ´ËÓ).
  • acute lymphatic leukemia =ALL
    ±Þ¼º ¸²ÇÁ¼º ¹éÇ÷º´(¡­àõÛÜúìÜ»).
  • acute lymphoblastic leukemia
    ±Þ¼º ¸²ÇÁ¸ð¼¼Æ÷¼º ¹éÇ÷º´.
  • acute lymphoblastic leukemia
    ±Þ¼º ¸²ÇÁ¸ð¼¼Æ÷¼º ¹éÇ÷º´.
  • acute lymphoblastic leukemia=ALL
    ±Þ¼º¸²ÇÁ±¸¼º¹éÇ÷º´,
  • acute megakaryocytic leukemia
    ±Þ¼º °ÅÇÙ±¸¼º ¹éÇ÷º´
  • acute monocytic leukemia
    ±Þ¼º ´Ü±¸(¼º) ¹éÇ÷º´(?ËÀË´ËÛËÑÌ´ËÓ).
  • acute monocytic leukemia
    ±Þ¼º ´Ü±¸(¼º) ¹éÇ÷º´(¡­Ó¤Ï¹àõÛÜúìÜ»).
  • acute myeloblastic leukemia
    ±Þ¼º °ñ¼ö¸ð¼¼Æ÷¼º ¹éÇ÷º´.
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Protein granule
    ´Ü¹éÁú°ú¸³
    [¿¾ ¿ë¾î] ´Ü¹éÁú°ú¸³
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • adherence protein
    ºÎÂø´Ü¹éÁú
  • circumsporozoite protein (CSP)
    Æ÷ÀÚ¼Òü¸·´Ü¹éÁú
  • protein layer
    ´Ü¹éÁúÃþ
  • stage-specific protein
    ¹ßÀ°´Ü°èƯÀ̴ܹéÁú
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukemia
    ¹éÇ÷º´(ÛÜúìÜ»)
  • accelerator protein
    ÃËÁø´Ü¹éÁú (õµòäÓ±ÛÜòõ)
  • acyl-carrier protein
    ¾Æ½Ç¿î¹Ý ´Ü¹éÁú (ê¡ÚæÓ±ÛÜòõ)
  • ada protein
    ada ´Ü¹éÁú
  • adhesion protein
    ºÎÂø´Ü¹éÁú(ݾó·Ó±ÛÜòõ)
  • aldosterone-induced protein
    ¾Ëµµ½ºÅ×·ÐÀ¯µµ ´Ü¹éÁú(ë¯ÓôÓ±ÛÜòõ)
  • A myeloma protein
    °ñ¼öÁ¾´Ü¹éÁú(ÍéâÐðþÓ±ÛÜòõ) A
  • androgen-binding protein
    ¾Èµå·ÎÀü°áÇÕ(Ì¿ùê) ´Ü¹éÁú(Ó±ÛÜòõ)
  • animal protein factor
    µ¿¹°´Ü¹éÁúÀÎÀÚ(ÔÑÚªÓ±ÛÜòõì×í­)
  • anion-transport protein
    À½À̿¿î¹Ý(ê¡Úõ) ´Ü¹éÁú(Ó±ÛÜòõ)
  • antifreeze protein
    Ç×°áºù´Ü¹éÁú(ù÷̿޼ӱÛÜòõ)
  • antitumor protein
    Ç×Á¾¾ç ´Ü¹éÁú(ù÷ðþåËÓ±ÛÜòõ)
  • antiviral protein
    Ç×(ù÷) ¹ÙÀÌ·¯½º ´Ü¹éÁú(Ó±ÛÜòõ)
  • A protein
    A ´Ü¹éÁú(Ó±ÛÜòõ)
  • azo-dye protein
    ¾ÆÁ¶»ö¼Ò ´Ü¹éÁú(ßäáÈÓ±ÛÜòõ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • aleukemic leukemia
    ¹«¹éÇ÷º´¼º¹éÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • lymphocytic leukemia
    ¸²ÇÁ±¸¼º¹éÇ÷º´
  • Bence-Jones protein
    º¥½º-Á¸½º´Ü¹é
  • C-reactive protein
    C-¹ÝÀÀ¼º´Ü¹éÁú
  • high protein diet
    °í´Ü¹é½ÄÀÌ
  • plasma protein
    Ç÷Àå´Ü¹éÁú
  • protein
    ´Ü¹é(Áú)
  • protein metabolism
    ´Ü¹é(Áú)´ë»ç
  • protein-losing enteropathy
    ´Ü¹é»ó½Ç¼ºÀ庴Áõ
  • protein-losing gastroenteropathy
    ´Ü¹é»ó½Ç¼ºÀ§ÀåÁõ
  • serum protein
    Ç÷û´Ü¹é
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AML Acute Myelogenous Leukemia
  Morphologic Classification(FABºÐ·ù)
   &n...
AML acute monocytic leukemia; acute mucosal lesion; acute myeloblastic leukemia; acute myelocytic leukem...
MAP malignant atrophic papulosis; mandibular angle plane; maturation-activated protein; maximal aerobic ...
MBP major basic protein; maltose-binding protein; management by policy; mannose-binding protein; mean bl...
RP radial pulse; radiopharmaceutical; rapid processing [of film]; Raynaud phenomenon; reactive protein;...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CGL 9--chronic granulocytic leukemia
ALL Acute lymphoblastic leukemia
AL Acute Leukemia
ALL Acute Lymphatic Leukemia
ALL Acute Lymphoid Leukemia
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´
    ¿ø¹ßÇÏ´Â Á¶Ç÷ Á¶Á÷À̳ª ¹éÇ÷º´ ¼¼Æ÷ÀÇ Á¾·ù¿¡ µû¶ó °ñ¼ö¼º, ¸²ÇÁ¼º, ´Ü±¸¼ºÀ¸·Î ³ª´µ¾îÁö°í Ư¼öÇÑ °ÍÀ¸·Î¼­ Àû¹éÇ÷º´, ÇüÁú ¼¼Æ÷¼º ¹éÇ÷º´, È£»ê±¸¼º ¶Ç´Â È£¿°±â¼º ¹éÇ÷º´ µîÀÌ ÀÖ´Ù.
  • acute lymphoblastic leukemia
    ±Þ¼º ¸²ÇÁ¼º ¹éÇ÷º´
    1. À¯¾Æ ¹× ÀþÀº ¼ºÀο¡ È£¹ßÇÏ´Â Áúȯ. À¯¾Æ ±Þ¼º ¹éÇ÷º´ÀÇ »ó´ç¼ö¸¦ Â÷ÁöÇÑ´Ù. À¯¾Æ¿¡¼­ÀÇ È£¹ß ¿¬·ÉÀº 4¼¼ ÀüÈÄ. ÃÖ±Ù È­Çпä¹ýÀ¸·Î º´¿¡ °É¸° À¯¾ÆÀÇ 90%°¡ ¿ÏÀü Ä¡À¯µÈ´Ù. ¿¹ÈÄ´Â ¿¬·É, ¸é¿ªÇ¥ÇöÇü ±×¸®°í ¼¼Æ÷ À¯ÀüÇÐÀûÀÎ º¯È­¿¡ ÀÇÇØ ¿µÇâÀ» ¹Þ´Â´Ù. 2. ȯÀÚÀÇ 90%°¡ ¹éÇ÷±¸ ¼¼Æ÷¿¡¼­ ÇÙÇü ÀÌ»óÀ» º¸ÀδÙ. ÀϺΠ¼¼Æ÷À¯Àü º¯È­°¡ ¼ºº°, ¿¬·É, ¸é¿ªÇ¥ÇöÇü °°Àº º¯ÀÌ¿ä¼Ò¿Í »ó°ü¾øÀÌ ¿¹ÈÄ¿¡ ´ëÇÑ Á¤º¸¸¦ ÁØ´Ù. 51-60 ¿°»öü »çÀÌÀÇ °í¹è¼ö¼ºÀÌ ¿¹Èİ¡ ÁÁÀº °ÍÀº ÀÌ¹Ì Àß ¾Ë·ÁÁ® ÀÖ´Ù.
  • acute megakaryocytic leukemia
    ±Þ¼º °ÅÇÙ±¸¼º ¹éÇ÷º´
  • acute mixed-lineage leukmia£¨±Þ¼º È¥ÇÕ-Á÷°è¼º ¹éÇ÷º´£©

    acute monocytic leukemia

    ±Þ¼º ´Ü±¸ ¹éÇ÷º´, ±Þ¼º ´Ü±¸¼º ¹éÇ÷º´
    ±Þ¼º ¹éÇ÷º´ÀÇ ÀÏÁ¾À̰í À¯¾à´Ü±¸°¡ ¹éÇ÷º´È­ÇÑ °ÍÀÌ´Ù. °ñ¼ö¿¡¼­ °ú¸³±¸°èÀÇ À¯¾à¼¼Æ÷¿Í ´Ü±¸°èÀÇ À¯¾à¼¼Æ÷°¡ È¥ÀçÇÏ´Â ¼ö°¡ ÀÖ°í ÀÌ °æ¿ì¿¡´Â ±Þ¼º °ñ¼ö´Ü±¸¼º ¹éÇ÷º´À̶ó°í ÇÑ´Ù.
  • acute myelocytic leukemia
    ±Þ¼º °ñ¼ö±¸¼º ¹éÇ÷º´
    ±Þ¼ºÀ¸·Î ¹ßº´ ÁøÇàµÇ´Â °ñ¼ö¼¼Æ÷ ±â¿øÀÇ ¹éÇ÷º´À¸·Î º¸Åë ¿­°ú ÇÔ²² ÀϾ´Ù.
  • acute myelomonoblastic leukemia
    ±Þ¼º °ñ¼ö ´Ü±¸¼º ¹éÇ÷º´
  • adult T cell leukemia
    ¼ºÀÎ T¼¼Æ÷ ¹éÇ÷º´
    ¹ßÁõ ¿¬·ÉÀº Æò±Õ 51¼¼, ÀϺ» Kyushu, Shikoku, Kii ¹Ýµµ Áö¹æ¿¡¼­ ´Ù¹ßÇϰí ÇǺΠħÀ± ¹× °£Àå, ºñÀå, ¸²ÇÁÀý Á¾´ë¸¦ ÈçÈ÷ º¼ ¼ö Àִµ¥ ºóÇ÷Àº ¾ø´ø°¡, À־ °æµµ, °ñ¼ö¿¡ÀÇ Ä§À±Àº º¸Åë ÇöÀúÇÏÁö ¾Ê´Ù. 50% »ýÁ¸Àº 4.4°³¿ù·Î ª´Ù. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Æ¯Â¡Àº ÇÙÀÌ ÀÌÇüÀÌ¸ç ºÐ¿±»ó, È­ÆÇ»ó µîÀ¸·Î Áø´Ü¿¡ »ç¿ëµÈ´Ù.
  • aleukemic leukemia
    ¹«¹éÇ÷º´¼º ¹éÇ÷º´
  • chronic granulocytic leukemia
    ¸¸¼º °ú¸³±¸ ¹éÇ÷º´, ¸¸¼º °ú¸³±¸¼º ¹éÇ÷º´
  • chronic myelogenous leukemia
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´
    ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´Àº Àå³âÃþ¿¡ ÁÖ·Î ¹ß»ýÇÏ¸ç ¹éÇ÷º´ÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÑ´Ù. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´Àº Á¶Ç÷¸ð¼¼Æ÷ ¼öÁØÀÇ ¾Ï¼º Áõ½ÄÀ¸·Î Áø¼º ÀûÇ÷±¸ Áõ°¡Áõ, Ç÷¼ÒÆÇ Áõ°¡Áõ ¹× °ñ¼ö ¼¶À¯È­Áõ°ú ÇÔ²² °ñ¼ö Áõ½Ä¼º ÁúȯÀ¸·Î ºÐ·ùµÈ´Ù. ¿°»öü 9¹ø°ú 22¹øÀÇ »óÈ£ ÀüÀ§·Î ÀÎÇÑ Çʶóµ¨ÇÇ¾Æ ¿°»öü¿Í ±× »ê¹°ÀÎ bcr-ablÀÌ 95% À̻󿡼­ ¾ç¼ºÀ¸·Î ÀÌ ÁúȯÀÇ º´Àΰú °ü°è°¡ ÀÖ´Â °ÍÀ¸·Î ÀÌÇØµÇ°í ÀÖ´Ù. ÁÖ Áõ»óÀº ºñÀå ºñ´ë·Î ÀÎÇÑ º¹ºÎ ÆØ¸¸ÀÌ Æ¯Â¡ÀûÀÌ¸ç ±×¿Ü °ú´ë»çÁõ µî ÀϹÝÀûÀÎ ¹éÇ÷º´ÀÇ Áõ»óÀÌ ÀÖ´Ù. Áø´ÜÀº Ç÷¾× ¼Ò°ß°ú °ñ¼ö ¼Ò°ß ±×¸®°í ¿°»öü ¹× ºÐÀÚ»ý¹°ÇÐ °Ë»ç¿¡ ÀÇÇÑ bcr-abl ÀÇ Áõ¸í¿¡ ÀÇÇÑ´Ù. ÀÌ ÁúȯÀÇ °æ°ú´Â ¾à 3³âÀÇ ¸¸¼º±â¸¦ Áö³ª°í Àüȯ±â¸¦ °Åó ±Þ¼º ¹éÇ÷º´À¸·Î ÀüȯµÇ¸ç À̶§´Â ÇöÀç ¾Ë·ÁÁø ¾î¶°ÇÑ Ä¡·á ¹æ¹ý¿¡µµ Àß ¹ÝÀÀÇÏÁö ¾Ê´Â´Ù. Ä¡·á´Â °ú°Å¿¡´Â busulfan À̶ó´Â Ç×¾ÏÁ¦°¡, ±Ù·¡¿¡´Â hydrea°¡ ÁÖ·Î »ç¿ëµÇ°í ÀÖÀ¸³ª À̵éÀº ±Þ¼º ¹éÇ÷º´À¸·ÎÀÇ ÀüȯÀ» ¸·Áö ¸øÇÏ¸ç ¹éÇ÷±¸ÀÇ Á¶Àý¿¡¸¸ µµ¿òÀÌ µÉ »Ó Çʶóµ¨ÇÇ¾Æ ¿°»öü°¡ ÀÖ´Â ¾Ï¼¼Æ÷¸¦ Á¦°ÅÇÏÁö´Â ¸øÇÑ´Ù. ±Ù·¡¿¡´Â homoharringtonine µîÀÇ ¾àÁ¦°¡ ¿¬±¸µÇ°í ÀÖ´Ù. 1990³â´ë ¿¡ µîÀåÇÑ ¾ËÆÄÀÎÅÍÆä·Ð ¿ä¹ýÀº ¾à 80%¿¡¼­ Ç÷¾× ¼Ò°ßÀÌ Á¤»óÈ­µÇ°í 20-30%¿¡¼­ Çʶóµ¨ÇÇ¾Æ ¿°»öü°¡ ¼Ò½ÇµÇ´Â µî ¿ì¼öÇÑ ¼ºÀûÀ» º¸À̰í ÀÖÀ¸³ª ±Þ¼º ¹éÇ÷º´À¸·ÎÀÇ ÀüȯÀ» ¸·Áö´Â ¸øÇÏ¸ç ¸¸¼º±â¸¦ ¾à 5³â Á¤µµ·Î ¿¬Àå½ÃŲ´Ù. ¸¸¼º °ñ¼ö¼º ¹éÇ÷º´À» ¿ÏÄ¡½Ãų ¼ö ÀÖ´Â À¯ÀÏÇÑ Ä¡·á ¹æ¹ýÀº µ¿Á¾ °ñ¼ö À̽ÄÀ¸·Î 55¼¼±îÁö ½ÃÇàÀÌ µÈ´Ù. °ñ¼ö ÀÌ½Ä ÈÄ Àå±â ¹«º´ »ýÁ¸À²Àº ¾à 60-70%ÀÌ¸ç Æ¯È÷ Áø´ÜµÈ ÈÄ 1³â À̳»¿¡ ½ÃÇàÇÏ´Â °ÍÀÌ ±Ç°íµÈ´Ù.
  • chronic myelomonocytic leukemia
    ¸¸¼º °ñ¼ö¼º ´Ü±¸ ¹éÇ÷º´
  • hairy cell leukemia
    À¯¸ð»ó ¼¼Æ÷¼º ¹éÇ÷º´
  • human T cell leukemia virus type II
    Á¦2Çü »ç¶÷ T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • human t-cell leukemia virus
    ÀÎü T ¼¼Æ÷ ¹éÇ÷º´ ¹ÙÀÌ·¯½º
  • lymphatic leukemia
    Àӯļº ¹éÇ÷º´
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
leukemia <haematology> An acute or chronic disease of unknown cause in man and other warm blooded animals that involves the blood forming organs, is characterised by an abnormal increase in the number of leucocytes in the tissues of the body with or without a corresponding increase of those in the circulating blood and is classified according of the type leucocyte most prominently involved.
(18 Nov 1997)
acetoacetyl-acyl carrier protein synthase <enzyme> E coli enzyme, that catalyses condensation of malonyl-acyl carrier protein plus acetyl-acyl carrier protein; not inhibited by cerulenin
Registry number: EC 2.3.1.-
Synonym: acetoacetyl-acp synthase
(26 Jun 1999)
acid soluble spore protein <molecular biology> A DNA binding protein in the spores of some bacteria, thought to stabilise the DNA in an A configuration, so protecting it from cleavage by enzymes or UV light.
(18 Nov 1997)
acute-phase protein <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor).
Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold.
Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability.
These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers.
See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity.
(25 Jun 1999)
acyl-(acyl-carrier-protein)-phospholipid acyltransferase <enzyme> Catalyses the formation of phosphatidylethanolamine from acyl-acyl carrier protein and 2-acyl-sn-glycero-3-phosphoethanolamine
Registry number: EC 2.3.1.40
Synonym: 2-acyl-gpe acyltransferase, 2-acylglycerophosphoethanolamine acyltransferase
(26 Jun 1999)
acyl-(acyl-carrier-protein)-UDP-N-acetylglucosamine acyltransferase <enzyme> E coli enzyme involved in lipid a biosynthesis; uses beta-hydroxymyristoyl-acyl carrier protein to form udp-3-monoacyl-n-acetylglucosamine; amino acid sequence given in second source
Registry number: EC 2.3.1.129
Synonym: udp-aguatransferase, lpxa protein, udp-n-acetylglucosamine-3-acyltransferase, udp-n-acetylglucosamine 3-o-acyltransferase, udp-3-o-(r-3-hydroxymyristoyl)glucosamine-n-acyltransferase, lpxd protein, fira gene product, fira protein
(26 Jun 1999)
acyl carrier protein <protein> A small (77 peptides long) protein which binds six other enzymes involved in fatty acid synthesis. It was first isolated in E. Coli bacteria.
(09 Oct 1997)
acyl carrier protein acylase <enzyme> From E coli
Registry number: EC 2.3.1.-
Synonym: acp acylase
(26 Jun 1999)
acyl protein synthetase <enzyme> Component of the fatty acid reductase complex of luminescent bacteria
Registry number: EC 2.3.1.-
Synonym: luxe gene product, fatty acyl-protein synthetase
(26 Jun 1999)
AKT1 protein kinase <enzyme> Human homolog of v-akt oncogene product
Registry number: EC 2.7.10.-
Synonym: akt1 protein, human
(26 Jun 1999)
AMP-activated protein kinase kinase <enzyme> An endogenous kinase kinase; reactivates the inactive form of AMP-activated protein kinase (AMP-pk); phosphorylates the 63-kD subunit of AMP-pk
Registry number: EC 2.7.1.-
Synonym: AMP-pk reactivator, hmg CoA reductase kinase kinase
(26 Jun 1999)
amyloid beta-protein A 4 kD protein, 39-43 amino acids long, expressed by a gene located on chromosome 21. It is the major protein subunit of the vascular and plaque amyloid filaments in individuals with alzheimer's disease and in aged individuals with trisomy 21 (down syndrome). The protein is found predominantly in the nervous system, but there have been reports of its presence in non-neural tissue.
(12 Dec 1998)
amyloid beta-protein precursor A precursor to the amyloid-beta protein (beta/a4). Alterations in the expression of the amyloid beta-protein precursor (abpp) gene, located on chromosome 21, plays a role in the development of the neuropathology common to both alzheimer disease and down syndrome. Abpp is associated with the extensive extracellular matrix secreted by neuronal cells. Upon cleavage, this precursor produces three proteins of varying amino acid lengths: 695, 751, and 770. The beta/a4 (695 amino acids) or beta-amyloid protein is the principal component of the extracellular amyloid in senile plaques found in alzheimer disease, down syndrome and, to a limited extent, in normal aging.
(12 Dec 1998)
amyloid precursor protein <protein> Individuals with Alzheimer's disease are characterised by extensive accumulation of amyloid in the brain, referred to as senile plaques. These consist of a core of amyloid fibrils surrounded by dystrophic neurites. The principal component of the amyloid fibrils is B/A4, a peptide derived from the larger APP. The specific role of amyloid protein is unclear but it is thought that amyloid deposits may cause neurons to degenerate. Amyloid deposits also occur in brains of older Down's Syndrome patients.
(04 May 1997)
amyloid protein Glycoprotein deposited extracellularly in tissues in amyloidosis. The glycoprotein may either derive from light chain of immunoglobulin (AIO (amyloid of immune origin): 5-18 kD glycoprotein, product of a single clone of plasma cells, the N terminal part of lambda or kappa light chain) or, in what used to be referred to as AUO, amyloid of unknown origin, from serum amyloid A (SAA), one of the acute phase proteins that increases many fold in inflammation. The polypeptides are organised as a _ pleated sheet making the material rather inert and insoluble. Minor protein components are also found. Should be distinguished from _ amyloid deposited in the brain and that is derived from amyloid precursor protein (see amyloidogenic glycoprotein.
(18 Nov 1997)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Myeloid-Lymphoid Leukemia Protein - »õâ Myeloid-lymphoid leukemia protein is a transcription factor that maintains high levels of HOMEOTIC GENE expression during development. The GENE for myeloid-lymphoid leukemia protein is commonly disrupted in LEUKEMIA and combines with over 40 partner genes to form FUSION ONCOGENE PROTEINS.
    Synonyms : Acute Lymphoblastic Leukemia Protein 1, MLL Proto-Oncogene Protein, Mixed-Lineage Leukemia Protein, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein, Proto-Oncogene Proteins MLL, Zinc Finger Protein HRX, MLL Proto Oncogene Protein
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukemia
    ¹éÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • leukemia
    ¹èÇ÷(±¸ °ú´Ù)Áõ !
  • protein
    ´Ü¹éÁú
  • coat protein
    ÇǸ· ´Ü¹é
  • conjugated protein
    º¹ÇÕ ´Ü¹éÁú
  • fish protein concentrate
    ¾îÀ° ³óÃà ´Ü¹é
  • protein
    ´Ü¹éÁú;´Ü¹éÁúÀÇ(À» ÇÔÀ¯ÇÏ´Â). proteinic a.
  • protein clock
    ´Ü¹éÁú ½Ã°è(´Ü¹éÁú ÁøÈ­ ¼Óµµ¸¦ Á¶ÀýÇÏ´Â °¡¼³Àû ü³» ±â±¸)
  • repressor protein
    ¾ïÁ¦ ´Ü¹é(Á¦¾î À¯ÀüÀÚ¿¡ ÀÇÇÏ¿© ¸¸µé¾îÁö´Â ´Ü¹é)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á